Malignant mesenchymal tumors are a diverse group of aggressive cancers originating from mesenchymal cells in connective tissues such as bone, muscle, cartilage, and fat. These tumors often invade surrounding tissues and metastasize to distant organs, posing significant treatment challenges. Among them, malignant mesenchymal tumors located in the distal femur are particularly rare, with limited reports detailing effective surgical and functional reconstruction strategies following wide resection.
View Article and Find Full Text PDFExtraskeletal chondrosarcomas are malignant tumors that develop in soft tissues rather than in bones. Unlike skeletal chondrosarcomas, which are more common, these tumors can occur in areas such as muscles, tendons, or fat. Their unique location in the body makes them distinct and sometimes challenging to diagnose and manage effectively.
View Article and Find Full Text PDFThis study reviews the long-term efficacy of short-segment posterior instrumentation and fusion (SSPIF) in treating thoracolumbar burst fractures. Authors retrospectively reviewed the radiographic results of single-level thoracolumbar burst fractures treated by SSPIF. Vertebral body height and wedge angles were measured on the preoperative, postoperative, and follow-up radiographic images.
View Article and Find Full Text PDFPurpose: Non-selective closed kinetic chain exercises (NSKCE) and or selective closed kinetic chain exercises (SCKCE) has been shown to increase Vastus medialis obliquus (VMO) muscle power in patellofemoral pain syndrome (PFPS). However, the superiority of the exercises to each other has not been shown. This study aimed to evaluating the effects of different exercises on the stiffness of the VMO and vastus lateralis (VL) muscles, pain management, functional scores, and thigh circumferences.
View Article and Find Full Text PDFWith the emergence of high-precision radiotherapy technologies such as stereotactic ablative radiotherapy (SABR), MR guided brachytherapy, image guided intensity modulated photon and proton radiotherapy and most recently daily adaptive radiotherapy, reirradiation is increasingly recognized as a viable treatment option for many patients. This includes those with recurrent, metastatic or new malignancies post initial radiotherapy. The primary challenge in reirradiation lies in balancing tumor control against the risk of severe toxicity from cumulative radiation doses to previously irradiated normal tissue.
View Article and Find Full Text PDF